Apoptosis: Refined and lethal

Nature Reviews Cancer

Volumn 13, Issue 2, 2013, Pages 79-

  Burgess, Darren J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABT 199; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; SELUMETINIB; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA CELL; LUNG CANCER; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; LYMPHOMA; NONHUMAN; NOTE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR REGRESSION; UPREGULATION;

EID: 84873038888     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3462     Document Type: Note

References (2)

1. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 6 Jan 2013 (doi:10.1038/ nm.3048)
2. Corcoran, R. B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 11 Dec 2012 (doi:10.1016/j.ccr.2012.11.007